ALX Oncology (NASDAQ:ALXO) Rating Reiterated by Cantor Fitzgerald

ALX Oncology (NASDAQ:ALXO)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports.

A number of other research analysts also recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of ALX Oncology in a research report on Wednesday. Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 price objective (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $18.83.

ALX Oncology Price Performance

NASDAQ:ALXO opened at $13.03 on Friday. ALX Oncology has a one year low of $3.94 and a one year high of $17.42. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24. The firm has a market cap of $653.45 million, a price-to-earnings ratio of -3.47 and a beta of 1.58. The firm’s fifty day moving average is $13.57 and its two-hundred day moving average is $11.67.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). Research analysts expect that ALX Oncology will post -3.33 EPS for the current year.

Insider Buying and Selling

In related news, insider Jaume Pons sold 20,000 shares of the company’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the transaction, the insider now owns 628,359 shares in the company, valued at approximately $7,006,202.85. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other ALX Oncology news, CEO Jason Lettmann acquired 4,400 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was bought at an average price of $11.31 per share, with a total value of $49,764.00. Following the purchase, the chief executive officer now owns 171,620 shares in the company, valued at $1,941,022.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jaume Pons sold 20,000 shares of the company’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the sale, the insider now directly owns 628,359 shares of the company’s stock, valued at approximately $7,006,202.85. The disclosure for this sale can be found here. Insiders own 50.30% of the company’s stock.

Institutional Trading of ALX Oncology

Large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its stake in ALX Oncology by 445.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after acquiring an additional 4,706 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of ALX Oncology in the 3rd quarter valued at approximately $168,000. SG Americas Securities LLC grew its stake in shares of ALX Oncology by 201.4% in the 4th quarter. SG Americas Securities LLC now owns 30,348 shares of the company’s stock valued at $452,000 after buying an additional 20,279 shares during the period. Barclays PLC grew its stake in shares of ALX Oncology by 57.1% in the 3rd quarter. Barclays PLC now owns 26,964 shares of the company’s stock valued at $129,000 after buying an additional 9,796 shares during the period. Finally, Forefront Analytics LLC purchased a new stake in shares of ALX Oncology in the 3rd quarter valued at approximately $66,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.